Transvaginal Mesh Lawsuit

Jury says Johnson & Johnson improperly marketed Risperdal

A jury in Arkansas ruled that Johnson & Johnson officials used deceptive tactics to market antipsychotic drug Risperdal, misleading doctors about the drug’s risks and improperly marketing it for unapproved uses, Bloomberg reports.

The decision in Arkansas marks the third such jury verdict against Johnson & Johnson over allegations that the pharmaceutical giant concealed Risperdal’s risks and tricked Medicaid regulators into paying more than they should have for the medication.

Juries also decided against the company in Louisiana and South Carolina.

A total ...

continue reading...

New J&J CEO involved in previous recall

A Newark Star-Ledger profile of Alex Gorsky, the new CEO of Johnson & Johnson, describes him as “the go-to man” during the company’s 1998 recall of Hismanal, an antihistamine that proved to have dangerous cardiovascular side effects.

Gorsky has succeeded previous chief executive officer William Weldon, who stepped down after a disastrous series of recalls. But the Star-Ledger mentions that some industry observers are questioning whether Gorsky played a part in marketing a hip implant that has generated thousands of lawsuits ...

continue reading...

Radiological devices had FDA whistle-blowers concerned

Six U.S. Food and Drug Administration doctors and scientists who claim the agency retaliated against them said they were trying to raise valid concerns about medical devices of unproven effectiveness, The Washington Post has reported.

The doctors and scientists, who worked in the office charged with reviewing medical devices, have filed suit in federal court alleging that the FDA monitored their personal e-mail accounts, and used information obtained that way to harass and improperly dismiss them.

According to The Washington Post, they ...

continue reading...

FDA looks to get devices on market more quickly

The U.S. Food and Drug Administration has announced a plan to get medical devices through the federal approval process and on the market more quickly.

According to the Wall Street Journal, the plan is an expansion of the FDA’s Innovation Pathway program.

The report says the plan will weigh factors such as how much risk patients are willing to accept with new devices. It quotes an agency spokesman as saying patients dealing with terminal illness are generally willing to accept a higher ...

continue reading...

Lawsuit: FDA whistle-blowers faced retaliation

A group of six doctors and scientists who worked for the U.S. Food and Drug Administration have sued the agency, claiming their personal e-mail was monitored after they warned Congress that the FDA was approving faulty medical devices, The Washington Post has reported.

All of the doctors and scientists who filed suit in federal court had worked in the office responsible for reviewing medical devices. They claim information gathered from the surveillance was used to harass and dismiss them, and their ...

continue reading...

Lawsuit accuses Johnson & Johnson of deception

A lawyer representing the state of Arkansas claims that Janssen, a unit of Johnson & Johnson, misled thousands of doctors in the state about the risks accompanying the anti-psychotic drug Risperdal, Bloomberg reports.

Arkansas is seeking more than $1.25 billion in penalties for alleged violations of the state’s deceptive-trade practices law.

Lawyers representing Arkansas argue that the company hid Risperdal’s diabetes risks, defrauded the state’s Medicaid program by failing to properly disclose those risks on the warning label, deceptively marketed the drug ...

continue reading...
Page 27 of 29 «...10202526272829